Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.

Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, Lehmann FF, Galinsky I, DiPietro H, Cummings K, Munshi NC, Stone RM, Neuberg DS, Soiffer R, Dranoff G, Ritz J, Nikiforow S.

Cancer Immunol Res. 2019 Jan;7(1):100-112. doi: 10.1158/2326-6066.CIR-18-0307. Epub 2018 Nov 5.

PMID:
30396908
2.

Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.

Murad JM, Baumeister SH, Werner L, Daley H, Trébéden-Negre H, Reder J, Sentman CL, Gilham D, Lehmann F, Snykers S, Sentman ML, Wade T, Schmucker A, Fanger MW, Dranoff G, Ritz J, Nikiforow S.

Cytotherapy. 2018 Jul;20(7):952-963. doi: 10.1016/j.jcyt.2018.05.001. Epub 2018 Jun 29.

PMID:
30180944
3.

Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies.

Murad JM, Graber DJ, Sentman CL.

Best Pract Res Clin Haematol. 2018 Jun;31(2):176-183. doi: 10.1016/j.beha.2018.03.003. Epub 2018 Mar 27. Review.

PMID:
29909918
4.

T-bet promotes potent antitumor activity of CD4+ CAR T cells.

Gacerez AT, Sentman CL.

Cancer Gene Ther. 2018 Jun;25(5-6):117-128. doi: 10.1038/s41417-018-0012-7. Epub 2018 Mar 7.

5.

Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression.

Gacerez AT, Hua CK, Ackerman ME, Sentman CL.

Cancer Immunol Immunother. 2018 May;67(5):749-759. doi: 10.1007/s00262-018-2124-1. Epub 2018 Feb 16.

PMID:
29453518
6.

NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.

Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P.

Cancer Res. 2018 Feb 15;78(4):1031-1043. doi: 10.1158/0008-5472.CAN-17-1788. Epub 2017 Dec 8.

7.

Computationally-driven identification of antibody epitopes.

Hua CK, Gacerez AT, Sentman CL, Ackerman ME, Choi Y, Bailey-Kellogg C.

Elife. 2017 Dec 4;6. pii: e29023. doi: 10.7554/eLife.29023.

8.

Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6.

Hua CK, Gacerez AT, Sentman CL, Ackerman ME.

Protein Eng Des Sel. 2017 Oct 1;30(10):713-721. doi: 10.1093/protein/gzx051.

9.

Exploiting natural killer group 2D receptors for CAR T-cell therapy.

Demoulin B, Cook WJ, Murad J, Graber DJ, Sentman ML, Lonez C, Gilham DE, Sentman CL, Agaugue S.

Future Oncol. 2017 Aug;13(18):1593-1605. doi: 10.2217/fon-2017-0102. Epub 2017 Jun 14. Review.

10.

NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors.

Godbersen C, Coupet TA, Huehls AM, Zhang T, Battles MB, Fisher JL, Ernstoff MS, Sentman CL.

Mol Cancer Ther. 2017 Jul;16(7):1335-1346. doi: 10.1158/1535-7163.MCT-16-0846. Epub 2017 May 12.

11.

Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.

Sentman ML, Murad JM, Cook WJ, Wu MR, Reder J, Baumeister SH, Dranoff G, Fanger MW, Sentman CL.

J Immunol. 2016 Dec 15;197(12):4674-4685. Epub 2016 Nov 14.

12.

Regulatory T cell-based therapies for autoimmunity.

Arellano B, Graber DJ, Sentman CL.

Discov Med. 2016 Aug;22(119):73-80. Review.

13.

Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.

Smits NC, Coupet TA, Godbersen C, Sentman CL.

Expert Opin Biol Ther. 2016 Sep;16(9):1105-12. doi: 10.1080/14712598.2016.1195364. Epub 2016 Jun 9. Review.

14.

Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy.

Rajasekaran K, Riese MJ, Rao S, Wang L, Thakar MS, Sentman CL, Malarkannan S.

Front Immunol. 2016 May 12;7:176. doi: 10.3389/fimmu.2016.00176. eCollection 2016. Review.

15.

How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.

Gacerez AT, Arellano B, Sentman CL.

J Cell Physiol. 2016 Dec;231(12):2590-8. doi: 10.1002/jcp.25419. Epub 2016 Jun 2. Review.

16.

Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.

Smits NC, Sentman CL.

J Clin Oncol. 2016 Apr 1;34(10):1131-3. doi: 10.1200/JCO.2015.64.9970. Epub 2016 Feb 16. No abstract available.

17.

A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells.

Gowen BG, Chim B, Marceau CD, Greene TT, Burr P, Gonzalez JR, Hesser CR, Dietzen PA, Russell T, Iannello A, Coscoy L, Sentman CL, Carette JE, Muljo SA, Raulet DH.

Elife. 2015 Nov 13;4. pii: e08474. doi: 10.7554/eLife.08474.

18.

Antibody humanization by structure-based computational protein design.

Choi Y, Hua C, Sentman CL, Ackerman ME, Bailey-Kellogg C.

MAbs. 2015;7(6):1045-57. doi: 10.1080/19420862.2015.1076600. Epub 2015 Aug 7.

19.

B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity.

Wu MR, Zhang T, Gacerez AT, Coupet TA, DeMars LR, Sentman CL.

J Immunol. 2015 Jun 1;194(11):5305-11. doi: 10.4049/jimmunol.1402517. Epub 2015 Apr 24.

20.

B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity.

Wu MR, Zhang T, DeMars LR, Sentman CL.

Gene Ther. 2015 Aug;22(8):675-84. doi: 10.1038/gt.2015.29. Epub 2015 Apr 1.

21.

DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma.

Wu MR, Zhang T, Alcon A, Sentman CL.

Cancer Immunol Immunother. 2015 Apr;64(4):409-18. doi: 10.1007/s00262-014-1648-2. Epub 2014 Dec 31.

22.

Biopolymer implants enhance the efficacy of adoptive T-cell therapy.

Stephan SB, Taber AM, Jileaeva I, Pegues EP, Sentman CL, Stephan MT.

Nat Biotechnol. 2015 Jan;33(1):97-101. doi: 10.1038/nbt.3104. Epub 2014 Dec 15.

23.

Targeting multiple types of tumors using NKG2D-coated iron oxide nanoparticles.

Wu MR, Cook WJ, Zhang T, Sentman CL.

Nanotechnology. 2014 Nov 28;25(47):475101. doi: 10.1088/0957-4484/25/47/475101. Epub 2014 Nov 5.

24.

Bispecific T-cell engagers for cancer immunotherapy.

Huehls AM, Coupet TA, Sentman CL.

Immunol Cell Biol. 2015 Mar;93(3):290-6. doi: 10.1038/icb.2014.93. Epub 2014 Nov 4. Review.

25.

NKG2D CARs as cell therapy for cancer.

Sentman CL, Meehan KR.

Cancer J. 2014 Mar-Apr;20(2):156-9. doi: 10.1097/PPO.0000000000000029. Review.

26.

The natural killer-activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells.

Talebian L, Fischer DA, Wu J, Channon JY, Sentman CL, Ernstoff MS, Meehan KR.

Transfusion. 2014 Jun;54(6):1515-21. doi: 10.1111/trf.12517. Epub 2014 Jan 22.

PMID:
24446786
27.

Challenges of creating effective chimeric antigen receptors for cancer therapy.

Sentman CL.

Immunotherapy. 2013 Aug;5(8):783-5. doi: 10.2217/imt.13.71. No abstract available.

28.

NKG2D ligands as therapeutic targets.

Spear P, Wu MR, Sentman ML, Sentman CL.

Cancer Immun. 2013 May 1;13:8. Print 2013. Review.

30.

NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.

Spear P, Barber A, Rynda-Apple A, Sentman CL.

Immunol Cell Biol. 2013 Jul;91(6):435-40. doi: 10.1038/icb.2013.17. Epub 2013 Apr 30.

31.

Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.

Zhang T, Sentman CL.

J Immunol. 2013 Mar 1;190(5):2455-63. doi: 10.4049/jimmunol.1201314. Epub 2013 Jan 25.

32.

Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma.

Meehan KR, Talebian L, Tosteson TD, Hill JM, Szczepiorkowski Z, Sentman CL, Ernstoff MS.

Biol Blood Marrow Transplant. 2013 Jan;19(1):129-37. doi: 10.1016/j.bbmt.2012.08.018. Epub 2012 Sep 10.

33.

An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.

Zhang T, Wu MR, Sentman CL.

J Immunol. 2012 Sep 1;189(5):2290-9. doi: 10.4049/jimmunol.1103495. Epub 2012 Jul 30.

34.

Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.

Spear P, Barber A, Rynda-Apple A, Sentman CL.

J Immunol. 2012 Jun 15;188(12):6389-98. doi: 10.4049/jimmunol.1103019. Epub 2012 May 14. Erratum in: J Immunol. 2014 Aug 1;193(3):1513.

35.

TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells.

Iyori M, Zhang T, Pantel H, Gagne BA, Sentman CL.

J Immunol. 2011 Sep 15;187(6):3087-95. doi: 10.4049/jimmunol.1003879. Epub 2011 Aug 10.

36.

Novel mobilization strategies to enhance autologous immune effector cells in multiple myeloma.

Talebian L, Wu JY, Fischer DA, Hill JM, Szczepiorkowski ZM, Ernstoff MS, Sentman CL, Meehan KR.

Front Biosci (Elite Ed). 2011 Jun 1;3:1500-8.

37.

NKG2D receptor regulates human effector T-cell cytokine production.

Barber A, Sentman CL.

Blood. 2011 Jun 16;117(24):6571-81. doi: 10.1182/blood-2011-01-329417. Epub 2011 Apr 25.

38.

Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.

Zhang T, Sentman CL.

Cancer Res. 2011 Mar 15;71(6):2066-76. doi: 10.1158/0008-5472.CAN-10-3200. Epub 2011 Jan 31.

39.

Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.

Barber A, Meehan KR, Sentman CL.

Gene Ther. 2011 May;18(5):509-16. doi: 10.1038/gt.2010.174. Epub 2011 Jan 6.

40.

Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected.

Meehan KR, Talebian L, Wu J, Hill JM, Szczepiorkowski ZM, Sentman CL, Ernstoff MS.

Cytotherapy. 2010 Dec;12(8):1013-21. doi: 10.3109/14653249.2010.515580. Epub 2010 Sep 27.

41.

Human decidual NK cells from gravid uteri and NK cells from cycling endometrium are distinct NK cell subsets.

Kopcow HD, Eriksson M, Mselle TF, Damrauer SM, Wira CR, Sentman CL, Strominger JL.

Placenta. 2010 Apr;31(4):334-8. doi: 10.1016/j.placenta.2010.01.003. Epub 2010 Feb 20.

42.

Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.

Barber A, Rynda A, Sentman CL.

J Immunol. 2009 Dec 1;183(11):6939-47. doi: 10.4049/jimmunol.0902000. Epub 2009 Nov 13. Erratum in: J Immunol. 2014 Aug 1;193(3):1513.

43.

Human uterine natural killer cells but not blood natural killer cells inhibit human immunodeficiency virus type 1 infection by secretion of CXCL12.

Mselle TF, Howell AL, Ghosh M, Wira CR, Sentman CL.

J Virol. 2009 Nov;83(21):11188-95. doi: 10.1128/JVI.00562-09. Epub 2009 Aug 19.

44.

Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.

Barber A, Sentman CL.

J Immunol. 2009 Aug 15;183(4):2365-72. doi: 10.4049/jimmunol.0900721. Epub 2009 Jul 22. Erratum in: J Immunol. 2014 Aug 1;193(3):1513.

45.

Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity.

Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R, Wang L, Nesbeth Y, Durant Y, Gewirtz AT, Sentman CL, Kedl R, Conejo-Garcia JR.

J Clin Invest. 2009 Aug;119(8):2231-44. doi: 10.1172/JCI37716. Epub 2009 Jul 13.

46.

Vascular endothelial growth factor C facilitates immune tolerance and endovascular activity of human uterine NK cells at the maternal-fetal interface.

Kalkunte SS, Mselle TF, Norris WE, Wira CR, Sentman CL, Sharma S.

J Immunol. 2009 Apr 1;182(7):4085-92. doi: 10.4049/jimmunol.0803769.

47.

Human uterine NK cells interact with uterine macrophages via NKG2D upon stimulation with PAMPs.

Basu S, Eriksson M, Pioli PA, Conejo-Garcia J, Mselle TF, Yamamoto S, Wira CR, Sentman CL.

Am J Reprod Immunol. 2009 Jan;61(1):52-61. doi: 10.1111/j.1600-0897.2008.00661.x.

48.

Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.

Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, Benencia F, Stan RV, Keler T, Sarobe P, Sentman CL, Conejo-Garcia JR.

Cancer Res. 2008 Sep 15;68(18):7684-91. doi: 10.1158/0008-5472.CAN-08-1167. Epub 2008 Sep 3.

49.

Estradiol regulates MICA expression in human endometrial cells.

Basu S, Pioli PA, Conejo-Garcia J, Wira CR, Sentman CL.

Clin Immunol. 2008 Nov;129(2):325-32. doi: 10.1016/j.clim.2008.07.005. Epub 2008 Aug 26.

50.

Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.

Barber A, Zhang T, Megli CJ, Wu J, Meehan KR, Sentman CL.

Exp Hematol. 2008 Oct;36(10):1318-28. doi: 10.1016/j.exphem.2008.04.010. Epub 2008 Jul 2.

Supplemental Content

Loading ...
Support Center